{
  "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
  "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 57,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/15",
  "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
  "deckJsonHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3.json",
  "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.085,
        "w": 0.235,
        "x": 0.318,
        "y": 0.375
      },
      "kind": "callout",
      "text": "NXC-201 67% improvement in response rates",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eaf51028-bb72-41be-b3aa-b402670dcc3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.6,
        "x": 0.2,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Complete Response Rates in BCMA-exposed multiple myeloma",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f997afee-82f7-4e38-9242-6b9e196d80fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.22,
        "x": 0.6,
        "y": 0.26
      },
      "kind": "image",
      "text": "Competitor logos and FDA approval years",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03ccb840-5d7e-4292-8c73-dd8931ae5fc9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: 49th EBMT (NXC-201) presentation, Elrexfio FDA approval label, Cohen et al 2023...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a84a68e-e169-4ae8-90a6-5485e398260c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Only CAR-T in BCMA-exposed multiple myeloma, a rapidly growing patient segment (2/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "893e1d9b-ccb2-4f74-830f-fc98fbc68c15",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 11,
      "beatId": "0124f715-f9b4-4df7-a2f6-852908af15ae",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 11,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "db157f78-2fa5-4d70-8683-8c727b29e9dd",
      "evidence": "The traction and clinical results slides provide evidence of the solution's effectiveness.",
      "position": 2,
      "objective": "How does NXC-201 perform in clinical trials?",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.8,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}